PATH study group Selected Research

Hizentra

1/2022	Analysis of relapse by inflammatory Rasch-built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy.
1/2021	Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy.
1/2020	Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.
1/2020	Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review.
1/2019	Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
1/2019	Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.
1/2018	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
1/2016	Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

PATH study group Research Topics

Disease

8	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 01/2022 - 01/2016
8	Polyneuropathies (Polyneuropathy) 01/2022 - 01/2016
1	Clinical Deterioration 01/2019

Drug/Important Bio-Agent (IBA)

8	HizentraIBA 01/2022 - 01/2016
7	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 01/2016
3	Intravenous Immunoglobulins (IVIG)FDA Link 01/2019 - 01/2016
1	Immunoglobulin G (IgG)IBA 01/2020

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2019